Updates from R&D Event

Summary by AI BETAClose X

HUTCHMED announced progress in its R&D programs, highlighting a new Antibody-Targeted Therapy Conjugate (ATTC) platform. The lead candidate, HMPL-A251, a PAM-HER2 ATTC, showed promising preclinical efficacy and safety. A Phase III trial of fruquintinib with sintilimab for second-line renal cell carcinoma achieved a progression-free survival of 22.2 months versus 6.9 months with axitinib or everolimus (HR: 0.37; p<0.0001). The objective response rate more than doubled to 60.5% versus 24.3%, with a median duration of response of 23.7 months compared to 11.3 months. Recruitment is complete for the SANOVO China Phase III study, and enrollment for the SAFFRON global Phase III study is expected to complete in late 2025. A new drug application submission for fanregratinib in China is planned for the first half of 2026.

Disclaimer*

UK 100

Latest directors dealings